Ipamorelin Canada — Best GHRP Research Guide 2026

If you’re researching growth hormone secretagogues, Ipamorelin stands out from the crowd. While older compounds like GHRP-2 and GHRP-6 were found to elevate cortisol and prolactin alongside growth hormone, Ipamorelin was specifically engineered to avoid those side effects. The result is one of the most selective GH-releasing peptides studied to date — and one of the most widely used in Canadian research settings.

This guide covers everything researchers need to know about Ipamorelin: how it works, what the peer-reviewed literature says, how it compares to other GHRPs, and how to source it in Canada.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide developed in the late 1990s by Novo Nordisk. It belongs to the Growth Hormone-Releasing Peptide (GHRP) class and acts as a selective agonist at the ghrelin receptor (GHS-R1a) expressed on pituitary somatotrophs.

Its defining characteristic is selectivity. In preclinical studies, Ipamorelin stimulates robust, dose-dependent growth hormone release without meaningfully elevating ACTH, cortisol, or prolactin — the hormonal side effects that limited earlier GHRPs. This selectivity makes it a cleaner research tool and a more controlled model compound for studying the GH axis.

Mechanism of Action

Ipamorelin binds to the GHS-R1a receptor on anterior pituitary somatotrophs, triggering an intracellular signalling cascade involving phospholipase C activation and intracellular calcium mobilisation. This leads to the exocytosis of growth hormone from secretory granules within pituitary cells.

This pathway is entirely distinct from the cAMP-mediated pathway activated by GHRH analogues like CJC-1295. Because the two mechanisms are independent, Ipamorelin and CJC-1295 can be combined to produce synergistic GH release — a combination that has become one of the most studied peptide stacks in current research literature.

Ipamorelin also exerts a mild suppressive effect on somatostatin (the endogenous GH inhibitor), further amplifying GH release. This dual action — receptor activation plus somatostatin suppression — explains why its GH-stimulating effect is disproportionately large relative to binding affinity alone.

Key Research Findings

Selective GH Release Without Cortisol Elevation

The landmark Ipamorelin study by Raun et al. (1998, European Journal of Endocrinology) established the compound’s selectivity profile. In rat models, Ipamorelin produced dose-dependent GH release comparable to GHRP-6 and GHRP-2, but without the concurrent increases in ACTH and cortisol observed with those compounds. This remains the foundational reference for Ipamorelin’s clean safety profile.

Dose-Dependent IGF-1 Elevation

Extended Ipamorelin administration in rodent models has consistently produced downstream elevations in IGF-1, the primary mediator of GH’s anabolic and metabolic effects. IGF-1 elevation has been observed after as little as two weeks of daily dosing, with levels remaining within physiological range rather than producing supraphysiological spikes.

Bone Mineral Density

Studies examining GHRPs in ovariectomised rat models — used as a model of post-menopausal bone loss — found that Ipamorelin administration was associated with significant improvements in bone mineral density and trabecular bone architecture, positioning it as a candidate for osteoporosis research.

Body Composition in Aged Animal Models

In aged rat models where GH secretion naturally declines, Ipamorelin administration restored GH pulsatility and was associated with reductions in adipose tissue alongside preservation of lean mass — findings consistent with the known lipolytic effects of elevated GH signalling.

Human Tolerability Data

A Phase II clinical trial by Helsinn Therapeutics investigated Ipamorelin in patients with postoperative ileus. While the compound did not advance to Phase III for that indication, the trial demonstrated human tolerability and added clinical safety data to the available literature — an important distinction from many research peptides that have only preclinical data.

Ipamorelin vs. Other GHRPs

For researchers studying GH axis function without wanting to introduce cortisol or prolactin as confounding variables, Ipamorelin offers a significantly cleaner experimental model than any of its GHRP predecessors.

Ipamorelin and CJC-1295: The Synergistic Stack

Ipamorelin is most commonly studied in combination with CJC-1295 (No DAC). The rationale: CJC-1295 activates GHRH receptors via a cAMP-dependent pathway, while Ipamorelin activates ghrelin receptors via a calcium-dependent pathway. When both are administered simultaneously, they produce synergistic GH release significantly greater than either compound alone — research has documented GH responses 4 to 6 times larger than monotherapy in some studies.

Panda Peptide supplies both Ipamorelin and CJC-1295 No DAC individually, as well as a pre-blended combo vial for researchers studying this stack.

Research Dosing Protocols

The following parameters are drawn from published research literature and provided for informational purposes only.

• Typical research dose: 100–200 mcg per administration
• Route: Subcutaneous injection (not orally bioavailable)
• Timing: Before sleep to align with natural nocturnal GH pulsatility, or in a fasted state to avoid insulin-mediated blunting
• Frequency: Once or twice daily in most published protocols
• Half-life: Approximately 2 hours

Reconstitution and Storage

• Reconstitution solvent: Bacteriostatic water — add slowly and swirl gently, do not shake
• Solubility: Water-soluble; dissolves without acetic acid or co-solvents
• Lyophilised storage: 2–8°C away from light; stable 24+ months
• Reconstituted solution: Refrigerate at 2–8°C; use within 30 days; avoid freeze-thaw cycles

Where to Buy Ipamorelin in Canada

Panda Peptide is a Canadian supplier of research-grade Ipamorelin, manufactured to 99%+ purity with third-party HPLC verification. We ship domestically across Canada with next-day shipping available and free shipping on orders over $200. Ipamorelin is available as a standalone 5mg vial or as part of the CJC-1295 No DAC + Ipamorelin combo vial.

Summary

Ipamorelin is the benchmark GHRP for researchers who need selective growth hormone stimulation without the cortisol, prolactin, and appetite confounds of older compounds. Its clean safety profile, well-characterised mechanism, human tolerability data, and compatibility with CJC-1295 make it one of the most useful peptides in the GH research toolkit. For Canadian researchers, Panda Peptide offers domestic supply at verified purity — available individually or as part of the CJC-1295 combo stack.

All products sold by Panda Peptide are for research purposes only. Not intended for human consumption. For use by qualified researchers in laboratory settings.

Ipamorelin Canada — Mechanism & Research Overview 2026

Researchers purchasing Ipamorelin Canada benefit from its highly selective growth hormone-releasing properties. Unlike broader GHRPs, Ipamorelin Canada triggers GH pulses with minimal cortisol or prolactin elevation, making it valuable for controlled studies. A key PubMed study on Ipamorelin selectivity confirmed its superior safety profile versus GHRP-2 and GHRP-6.

Buy Ipamorelin Canada — Panda Peptide Research Supply

For verified Ipamorelin Canada supply, Panda Peptide provides COA-tested peptides for qualified researchers. Our peptide shop carries Ipamorelin Canada alongside related compounds. Use the peptide calculator to plan your Ipamorelin Canada research dosage schedule. Compare with CJC-1295 Canada for combination research protocols.

Ipamorelin Canada Research Studies — What the Science Says

Multiple peer-reviewed investigations into Ipamorelin Canada-class compounds have documented consistent GH elevation without significant IGF-1 desensitisation over prolonged treatment windows. Researchers in Canada sourcing Ipamorelin Canada for in vitro studies should note that purity standards above 99% HPLC are essential for reproducible results. Ipamorelin Canada from Panda Peptide meets this threshold and is supported by a full certificate of analysis.

Ipamorelin Canada is one of the best-studied selective growth hormone secretagogues. Researchers across Canada rely on Ipamorelin Canada for its clean GH release profile and absence of appetite stimulation side effects seen with older GHRPs. Whether you are conducting acute or chronic studies, Ipamorelin Canada from Panda Peptide delivers consistent, reproducible results for your research.